Whether you're looking for a way to raise the stream of passive income your portfolio produces or you simply want to outperform benchmark averages, adding some dividend-paying stocks to your portfolio ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Today, Pfizer said that its phase 3 TALAPRO 2 trial of PARP drug Talzenna (talazoparib) in combination with its Astellas-partnered anti-androgen therapy Xtandi (enzalutamide) reduced radiographic ...

combined with Xtandi (enzalutamide), which reported new data from the TALAPRO-2 study at ASCO GU, including a 37% reduction in rPFS in an all-comer population.

Karim Fizazi presented the final overall survival results from the TALAPRO-2 trial, which evaluated talazoparib + enzalutamide as first-line treatment for HRR-deficient metastatic castration-resistant ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...

New Diagnostics, AI Breakthroughs, and Next-Gen Therapies Are Transforming the Oncology Market. The oncology sector is experiencing <stron ...